Identification

Name
Masoprocol
Accession Number
DB00179  (APRD01084, DB05900)
Type
Small Molecule
Groups
Approved, Investigational
Description

A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]

Structure
Thumb
Synonyms
  • erythro-nordihydroguaiaretic acid
  • Masoprocolum
  • meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane
  • meso-2,3-bis(3,4-dihydroxyphenylmethyl)butane
  • meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
  • meso-4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)
  • meso-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol
  • meso-NDGA
  • meso-nordihydroguaiaretic acid
  • meso-β,γ-dimethyl-α,δ-bis(3,4-dihydroxyphenyl)butan
  • Nordihydroguaiaretic acid
External IDs
CHX 100 / CHX-100 / INSM-18 / INSM18 / NSC-4291
International/Other Brands
Actinex
Categories
UNII
7BO8G1BYQU
CAS number
27686-84-6
Weight
Average: 302.3649
Monoisotopic: 302.151809192
Chemical Formula
C18H22O4
InChI Key
HCZKYJDFEPMADG-TXEJJXNPSA-N
InChI
InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+
IUPAC Name
4-[(2S,3R)-3-[(3,4-dihydroxyphenyl)methyl]-2-methylbutyl]benzene-1,2-diol
SMILES
C[[email protected]@H](CC1=CC(O)=C(O)C=C1)[[email protected]](C)CC1=CC(O)=C(O)C=C1

Pharmacology

Indication

Used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated).

Structured Indications
Not Available
Pharmacodynamics

Masoprocol is a novel antineoplastic agent. It is not known exactly how masoprocol works. Laboratory experiments have shown that masoprocol prevents cells similar to the ones found in actinic keratoses from multiplying. Masoprocol was withdrawn from the U.S. market in June 1996.

Mechanism of action

Although the exact mechanism of action is not known, studies have shown that masoprocol is a potent 5-lipoxygenase inhibitor and has antiproliferative activity against keratinocytes in tissue culture, but the relationship between this activity and its effectiveness in actinic keratoses is unknown. Masoprocol also inhibits prostaglandins but the significance of this action is not yet known.

TargetActionsOrganism
AArachidonate 5-lipoxygenase
inhibitor
Human
USex hormone-binding globulinNot AvailableHuman
Absorption

Less than 1%-2% is absorbed through the skin over a 4-day period following application.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of overdose or allergic reaction include bluish coloration of skin, dizziness, severe, or feeling faint, wheezing or trouble in breathing.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Masoprocol is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Masoprocol is combined with 5-androstenedione.Experimental, Illicit
AbciximabMasoprocol may increase the anticoagulant activities of Abciximab.Approved
AcebutololMasoprocol may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Acemetacin.Approved
AcenocoumarolMasoprocol may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Masoprocol.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Masoprocol.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinMasoprocol may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Alendronic acid.Approved
AliskirenMasoprocol may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Alminoprofen.Experimental
AlprenololMasoprocol may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Masoprocol.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Amcinonide.Approved
AmikacinMasoprocol may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMasoprocol may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinMasoprocol may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodMasoprocol may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Masoprocol is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Masoprocol is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Anisodamine.Investigational
annamycinMasoprocol may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Antipyrine.Approved
Antithrombin III humanMasoprocol may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanMasoprocol may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Masoprocol is combined with Apocynin.Investigational
ApramycinMasoprocol may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Masoprocol is combined with Apremilast.Approved, Investigational
ArbekacinMasoprocol may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinMasoprocol may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanMasoprocol may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMasoprocol may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Atamestane.Investigational
AtenololMasoprocol may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Masoprocol.Approved
BalsalazideMasoprocol may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminMasoprocol may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMasoprocol may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinMasoprocol may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Masoprocol.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Masoprocol.Approved
BenorilateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Masoprocol.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Betamethasone.Approved, Vet Approved
BetaxololMasoprocol may decrease the antihypertensive activities of Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Masoprocol.Approved, Investigational
BevantololMasoprocol may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Masoprocol.Approved, Investigational
BisoprololMasoprocol may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMasoprocol may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololMasoprocol may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bucillamine.Investigational
BucindololMasoprocol may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bufexamac.Experimental
BufuralolMasoprocol may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bumadizone.Experimental
BumetanideMasoprocol may decrease the diuretic activities of Bumetanide.Approved
BupranololMasoprocol may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Masoprocol.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Masoprocol.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Masoprocol.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Masoprocol.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Masoprocol is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Masoprocol.Approved
CarprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololMasoprocol may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMasoprocol may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Castanospermine.Experimental
CeliprololMasoprocol may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMasoprocol may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Masoprocol.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Masoprocol.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Masoprocol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Masoprocol.Approved
CinoxacinMasoprocol may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidMasoprocol may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Masoprocol.Vet Approved
CloranololMasoprocol may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Masoprocol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Masoprocol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Masoprocol is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Masoprocol.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Masoprocol.Approved, Investigational
CyclosporineMasoprocol may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Masoprocol.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when Masoprocol is combined with D-Limonene.Investigational
Dabigatran etexilateMasoprocol may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMasoprocol may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMasoprocol may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanMasoprocol may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinMasoprocol may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Masoprocol is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Masoprocol.Experimental
DesirudinMasoprocol may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Masoprocol.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Masoprocol.Approved, Investigational
DextranMasoprocol may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Masoprocol may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Masoprocol may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Masoprocol may increase the anticoagulant activities of Dextran 75.Approved
DibekacinMasoprocol may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Masoprocol.Approved, Vet Approved
DicoumarolMasoprocol may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Masoprocol is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Masoprocol.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Masoprocol.Approved
DihydrostreptomycinMasoprocol may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Masoprocol.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Masoprocol.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Masoprocol.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Masoprocol.Approved, Investigational
DoxorubicinMasoprocol may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneMasoprocol may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Masoprocol is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Masoprocol is combined with E-6201.Investigational
Edetic AcidMasoprocol may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMasoprocol may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Masoprocol.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Masoprocol.Approved
EnoxacinMasoprocol may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinMasoprocol may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Masoprocol.Experimental
EpanololMasoprocol may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Masoprocol is combined with Epirizole.Approved
EpirubicinMasoprocol may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMasoprocol may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Masoprocol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Masoprocol.Approved
EquileninThe risk or severity of adverse effects can be increased when Masoprocol is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Equilin.Approved
EsmololMasoprocol may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Estrone sulfate.Approved
Etacrynic acidMasoprocol may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Masoprocol.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ethenzamide.Experimental
Ethyl biscoumacetateMasoprocol may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etofenamate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Masoprocol is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Masoprocol is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Masoprocol.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Feprazone.Experimental
Ferulic acidMasoprocol may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Masoprocol.Approved, Investigational
FleroxacinMasoprocol may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Masoprocol.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fludrocortisone.Approved
FluindioneMasoprocol may increase the anticoagulant activities of Fluindione.Investigational
FlumequineMasoprocol may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Masoprocol.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Flurbiprofen.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Masoprocol.Approved, Nutraceutical, Vet Approved
FondaparinuxMasoprocol may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMasoprocol may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Masoprocol.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Masoprocol.Approved
FramycetinMasoprocol may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMasoprocol may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateMasoprocol may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinMasoprocol may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinMasoprocol may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Masoprocol.Approved, Withdrawn
GemifloxacinMasoprocol may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinMasoprocol may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMasoprocol may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMasoprocol may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GitoformateGitoformate may decrease the cardiotoxic activities of Masoprocol.Experimental
GPX-150Masoprocol may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinMasoprocol may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Masoprocol is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Masoprocol is combined with HE3286.Investigational
HeparinMasoprocol may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Higenamine.Investigational
HydralazineMasoprocol may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Masoprocol.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Masoprocol.Approved, Investigational
Hygromycin BMasoprocol may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Masoprocol is combined with Icatibant.Approved
IdarubicinMasoprocol may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxMasoprocol may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Masoprocol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Masoprocol.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Masoprocol.Approved
IndenololMasoprocol may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Indoprofen.Withdrawn
INNO-206Masoprocol may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Masoprocol.Approved, Investigational
IsepamicinMasoprocol may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Masoprocol is combined with Istaroxime.Investigational
KanamycinMasoprocol may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Masoprocol.Approved
LabetalolMasoprocol may decrease the antihypertensive activities of Labetalol.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Masoprocol.Experimental
LandiololMasoprocol may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Masoprocol.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Masoprocol.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Leflunomide.Approved, Investigational
LepirudinMasoprocol may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanMasoprocol may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololMasoprocol may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMasoprocol may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Masoprocol.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Masoprocol.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Masoprocol.Approved
LonazolacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Masoprocol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Masoprocol.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Masoprocol.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Magnesium salicylate.Approved
ME-609The risk or severity of adverse effects can be increased when Masoprocol is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mefenamic acid.Approved
MelagatranMasoprocol may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Meloxicam.Approved, Vet Approved
MepindololMasoprocol may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineMasoprocol may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Masoprocol is combined with Metamizole.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Masoprocol.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Masoprocol.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Masoprocol.Experimental
MetipranololMasoprocol may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Masoprocol.Approved
MetoprololMasoprocol may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideMasoprocol may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinMasoprocol may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Masoprocol.Approved
MizoribineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Masoprocol.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Masoprocol.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mycophenolic acid.Approved
NadololMasoprocol may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMasoprocol may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMasoprocol may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Naftifine.Approved
Nalidixic AcidMasoprocol may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Masoprocol is combined with NCX 1022.Investigational
NeamineMasoprocol may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinMasoprocol may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinMasoprocol may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nepafenac.Approved
NetilmicinMasoprocol may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nitroaspirin.Investigational
NorfloxacinMasoprocol may increase the neuroexcitatory activities of Norfloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Masoprocol.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Masoprocol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Olopatadine.Approved
OlsalazineMasoprocol may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Masoprocol.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Orgotein.Vet Approved
OtamixabanMasoprocol may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Masoprocol.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Oxaprozin.Approved
Oxolinic acidMasoprocol may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololMasoprocol may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Masoprocol.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Paramethasone.Approved
ParomomycinMasoprocol may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Parthenolide.Investigational
PazufloxacinMasoprocol may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMasoprocol may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololMasoprocol may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateMasoprocol may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Masoprocol.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Masoprocol.Experimental
PhenindioneMasoprocol may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonMasoprocol may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pimecrolimus.Approved, Investigational
PindololMasoprocol may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidMasoprocol may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinMasoprocol may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMasoprocol may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pirfenidone.Approved, Investigational
Piromidic acidMasoprocol may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pirprofen.Experimental
PlazomicinMasoprocol may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinMasoprocol may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Masoprocol.Approved
PractololMasoprocol may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Masoprocol.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Masoprocol can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Propacetamol.Approved, Investigational
PropranololMasoprocol may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Proquazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Masoprocol.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Masoprocol.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Masoprocol.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Masoprocol.Vet Approved
Protein CMasoprocol may increase the anticoagulant activities of Protein C.Approved
Protein S humanMasoprocol may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMasoprocol may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinMasoprocol may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Masoprocol is combined with PTC299.Investigational
PuromycinMasoprocol may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Masoprocol.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Masoprocol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Masoprocol.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Masoprocol.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinMasoprocol may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinMasoprocol may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Risedronate.Approved, Investigational
RivaroxabanMasoprocol may increase the anticoagulant activities of Rivaroxaban.Approved
RosoxacinMasoprocol may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinMasoprocol may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinMasoprocol may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Masoprocol.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Masoprocol.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Masoprocol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Masoprocol is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Masoprocol is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Masoprocol is combined with Serrapeptase.Investigational
SisomicinMasoprocol may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinMasoprocol may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Masoprocol.Approved
SotalolMasoprocol may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMasoprocol may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinMasoprocol may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinMasoprocol may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Masoprocol.Approved
SpironolactoneMasoprocol may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Masoprocol is combined with SRT501.Investigational
StreptomycinMasoprocol may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMasoprocol may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Masoprocol is combined with Sulindac.Approved
SulodexideMasoprocol may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Masoprocol.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Suxibuzone.Experimental
TacrolimusMasoprocol may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Masoprocol.Approved
TalinololMasoprocol may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Masoprocol.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Masoprocol.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Masoprocol is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Masoprocol.Approved, Investigational
TemafloxacinMasoprocol may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Masoprocol.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Teriflunomide.Approved
TertatololMasoprocol may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololMasoprocol may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tixocortol.Approved
TobramycinMasoprocol may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tolmetin.Approved
TorasemideMasoprocol may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Masoprocol.Approved
TranilastThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Masoprocol.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Masoprocol.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Masoprocol.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Masoprocol is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMasoprocol may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Masoprocol.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Masoprocol is combined with Triptolide.Investigational
TrovafloxacinMasoprocol may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinMasoprocol may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Masoprocol.Approved
ValrubicinMasoprocol may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Masoprocol.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Masoprocol.Approved
WarfarinMasoprocol may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMasoprocol may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Masoprocol.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinMasoprocol may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinMasoprocol may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14325
KEGG Drug
D04862
KEGG Compound
C10719
PubChem Compound
71398
PubChem Substance
46508042
ChemSpider
64490
BindingDB
22372
ChEBI
73468
ChEMBL
CHEMBL313972
Therapeutic Targets Database
DNC001037
PharmGKB
PA164746493
IUPHAR
4265
Guide to Pharmacology
GtP Drug Page
Wikipedia
Masoprocol
ATC Codes
L01XX10 — Masoprocol
MSDS
Download (69 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentProstate Cancer1

Pharmacoeconomics

Manufacturers
  • Univ arizona cancer center
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)185.5 °CPhysProp
logP5.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0136 mg/mLALOGPS
logP3.44ALOGPS
logP4.76ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)9.21ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area80.92 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity86.62 m3·mol-1ChemAxon
Polarizability33.63 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.935
Blood Brain Barrier-0.5361
Caco-2 permeable+0.6215
P-glycoprotein substrateSubstrate0.6654
P-glycoprotein inhibitor INon-inhibitor0.9519
P-glycoprotein inhibitor IINon-inhibitor0.9144
Renal organic cation transporterNon-inhibitor0.886
CYP450 2C9 substrateNon-substrate0.7194
CYP450 2D6 substrateNon-substrate0.8261
CYP450 3A4 substrateNon-substrate0.5171
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8891
CYP450 2D6 inhibitorInhibitor0.8262
CYP450 2C19 inhibitorInhibitor0.8628
CYP450 3A4 inhibitorNon-inhibitor0.5833
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5322
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8614
BiodegradationNot ready biodegradable0.9632
Rat acute toxicity2.1491 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.6288
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-00di-0901000000-c0d0caa2c363f17f6c94
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTOF , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0911000000-ad449f20d75c55f665cc
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzylbutane lignans. These are lignan compounds containing a 2,3-dibenzylbutane moiety.
Kingdom
Organic compounds
Super Class
Lignans, neolignans and related compounds
Class
Dibenzylbutane lignans
Sub Class
Not Available
Direct Parent
Dibenzylbutane lignans
Alternative Parents
Phenylpropanes / Catechols / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Dibenzylbutane lignan skeleton / Phenylpropane / Catechol / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Benzenoid / Monocyclic benzene moiety / Organic oxygen compound / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
nordihydroguaiaretic acid (CHEBI:73468) / Lignans (C10719)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Iron ion binding
Specific Function
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name
ALOX5
Uniprot ID
P09917
Uniprot Name
Arachidonate 5-lipoxygenase
Molecular Weight
77982.595 Da
References
  1. Audouin C, Mestdagh N, Lassoie MA, Houssin R, Henichart JP: N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase. Bioorg Med Chem Lett. 2001 Mar 26;11(6):845-8. [PubMed:11277534]
  2. Lambert JD, Meyers RO, Timmermann BN, Dorr RT: Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. J Chromatogr B Biomed Sci Appl. 2001 Apr 15;754(1):85-90. [PubMed:11318430]
  3. Azadzoi KM, Heim VK, Tarcan T, Siroky MB: Alteration of urothelial-mediated tone in the ischemic bladder: role of eicosanoids. Neurourol Urodyn. 2004;23(3):258-64. [PubMed:15098224]
  4. West M, Mhatre M, Ceballos A, Floyd RA, Grammas P, Gabbita SP, Hamdheydari L, Mai T, Mou S, Pye QN, Stewart C, West S, Williamson KS, Zemlan F, Hensley K: The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice. J Neurochem. 2004 Oct;91(1):133-43. [PubMed:15379894]
  5. Jeon SB, Ji KA, You HJ, Kim JH, Jou I, Joe EH: Nordihydroguaiaretic acid inhibits IFN-gamma-induced STAT tyrosine phosphorylation in rat brain astrocytes. Biochem Biophys Res Commun. 2005 Mar 11;328(2):595-600. [PubMed:15694390]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Androgen binding
Specific Function
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
Gene Name
SHBG
Uniprot ID
P04278
Uniprot Name
Sex hormone-binding globulin
Molecular Weight
43778.755 Da
References
  1. Hong H, Branham WS, Ng HW, Moland CL, Dial SL, Fang H, Perkins R, Sheehan D, Tong W: Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and alpha-fetoprotein. Toxicol Sci. 2015 Feb;143(2):333-48. doi: 10.1093/toxsci/kfu231. Epub 2014 Oct 27. [PubMed:25349334]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible f...
Gene Name
CYP2J2
Uniprot ID
P51589
Uniprot Name
Cytochrome P450 2J2
Molecular Weight
57610.165 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:34